Head-to-head comparison of 99mTc-PSMA and 99mTc-MDP SPECT/CT in diagnosing prostate cancer bone metastasis: a prospective, comparative imaging trial
Abstract The most common site of metastasis of prostate cancer (PCa) is bone. Skeletal-related events can increase the risk of death in patients with PCa by 28%. Due to the low detection rate of lesions in patients with low prostate-specific antigen (PSA) levels, the value of 99mTc methylene diphosp...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2022-09-01
|
| Series: | Scientific Reports |
| Online Access: | https://doi.org/10.1038/s41598-022-20280-x |
| _version_ | 1811202823064387584 |
|---|---|
| author | Yu Zhang Zhiyi Lin Tao Li Yongbao Wei Mingdian Yu Liefu Ye Yuqing Cai Shengping Yang Yanmin Zhang Yuanying Shi Wenxin Chen |
| author_facet | Yu Zhang Zhiyi Lin Tao Li Yongbao Wei Mingdian Yu Liefu Ye Yuqing Cai Shengping Yang Yanmin Zhang Yuanying Shi Wenxin Chen |
| author_sort | Yu Zhang |
| collection | DOAJ |
| description | Abstract The most common site of metastasis of prostate cancer (PCa) is bone. Skeletal-related events can increase the risk of death in patients with PCa by 28%. Due to the low detection rate of lesions in patients with low prostate-specific antigen (PSA) levels, the value of 99mTc methylene diphosphonate (99mTc-MDP) bone scintigraphy is limited. Prostate-specific membrane antigen (PSMA) is a small molecular probe that can efficiently and specifically detect PCa lesions. This prospective study aimed to evaluate the difference between 99mTc-PSMA single-photon emission computed tomography (SPECT)/CT and 99mTc-MDP SPECT/CT in the detection of bone metastasis in PCa. A total of 74 men with pathologically confirmed PCa from October 2019 to November 2021 were prospectively enrolled in this study. The median age was 70 (range, 55–87) years. All patients underwent both 99mTc-PSMA SPECT/CT and 99mTc-MDP SPECT/CT at an average interval of 12.1 (range, 1–14) days. The detected imaging-positive bone lesions were scored as “typical metastasis” or “equivocal metastasis” by a standard reporting schema. Subsequent therapy modality details were observed through follow-up. Twenty-five of the 74 patients were diagnosed with bone metastases. 99mTc-PSMA SPECT/CT and 99mTc-MDP SPECT/CT detected 20 and 18 bone metastases, with sensitivities of 80.0% (20/25) and 72.0% (18/25), specificities of 100.0% (49/49) and 81.3% (40/49), and AUCs of 88.0% and 84.9%, respectively. There was a significant difference in the AUC between the two imaging methods (P < 0.001). In an analysis of the number of bone metastasis lesions, the proportion of “typical metastasis” versus “equivocal metastasis” detected by the two imaging methods was 26.3:1 (PSMA) and 2.9:1 (MDP), and the difference was statistically significant (P = 0.005). There was a significant difference in the detection of bone metastatic lesions by 99mTc-PSMA and 99mTc-MDP when the maximum diameter of the lesions was ≤ 0.6 cm (P < 0.05). The optimal cut-off value for PSA was 2.635 ng/mL (PSMA) and 15.275 ng/mL (MDP). 99mTc-PSMA SPECT/CT led to a change in management to a more individualized therapy modality for 11 of 74 men (14.9%). 99mTc-PSMA SPECT/CT was superior to 99mTc-MDP SPECT/CT in the detection of bone metastases in PCa, especially for small lesions and in patients with low PSA levels, and demonstrated an additional benefit of providing information on extraskeletal metastases. With regard to therapy, 99mTc-PSMA scans might have utility in improving the subsequent therapy modality. |
| first_indexed | 2024-04-12T02:45:06Z |
| format | Article |
| id | doaj.art-334b05fe983e4f75a964b24405ab6462 |
| institution | Directory Open Access Journal |
| issn | 2045-2322 |
| language | English |
| last_indexed | 2024-04-12T02:45:06Z |
| publishDate | 2022-09-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Scientific Reports |
| spelling | doaj.art-334b05fe983e4f75a964b24405ab64622022-12-22T03:51:11ZengNature PortfolioScientific Reports2045-23222022-09-0112111110.1038/s41598-022-20280-xHead-to-head comparison of 99mTc-PSMA and 99mTc-MDP SPECT/CT in diagnosing prostate cancer bone metastasis: a prospective, comparative imaging trialYu Zhang0Zhiyi Lin1Tao Li2Yongbao Wei3Mingdian Yu4Liefu Ye5Yuqing Cai6Shengping Yang7Yanmin Zhang8Yuanying Shi9Wenxin Chen10Department of Nuclear Medicine, Shengli Clinical Medical College of Fujian Medical University, Fujian Provincial HospitalDepartment of Nuclear Medicine, Shengli Clinical Medical College of Fujian Medical University, Fujian Provincial HospitalDepartment of Urology, Shengli Clinical Medical College of Fujian Medical University, Fujian Provincial HospitalDepartment of Urology, Shengli Clinical Medical College of Fujian Medical University, Fujian Provincial HospitalDepartment of Nuclear Medicine, Shengli Clinical Medical College of Fujian Medical University, Fujian Provincial HospitalDepartment of Urology, Shengli Clinical Medical College of Fujian Medical University, Fujian Provincial HospitalDepartment of Medicaledical Department, Shengli Clinical Medical College of Fujian Medical University, Fujian Provincial HospitalDepartment of Nuclear Medicine, Shengli Clinical Medical College of Fujian Medical University, Fujian Provincial HospitalDepartment of Nuclear Medicine, Shengli Clinical Medical College of Fujian Medical University, Fujian Provincial HospitalDepartment of Nuclear Medicine, Shengli Clinical Medical College of Fujian Medical University, Fujian Provincial HospitalDepartment of Nuclear Medicine, Shengli Clinical Medical College of Fujian Medical University, Fujian Provincial HospitalAbstract The most common site of metastasis of prostate cancer (PCa) is bone. Skeletal-related events can increase the risk of death in patients with PCa by 28%. Due to the low detection rate of lesions in patients with low prostate-specific antigen (PSA) levels, the value of 99mTc methylene diphosphonate (99mTc-MDP) bone scintigraphy is limited. Prostate-specific membrane antigen (PSMA) is a small molecular probe that can efficiently and specifically detect PCa lesions. This prospective study aimed to evaluate the difference between 99mTc-PSMA single-photon emission computed tomography (SPECT)/CT and 99mTc-MDP SPECT/CT in the detection of bone metastasis in PCa. A total of 74 men with pathologically confirmed PCa from October 2019 to November 2021 were prospectively enrolled in this study. The median age was 70 (range, 55–87) years. All patients underwent both 99mTc-PSMA SPECT/CT and 99mTc-MDP SPECT/CT at an average interval of 12.1 (range, 1–14) days. The detected imaging-positive bone lesions were scored as “typical metastasis” or “equivocal metastasis” by a standard reporting schema. Subsequent therapy modality details were observed through follow-up. Twenty-five of the 74 patients were diagnosed with bone metastases. 99mTc-PSMA SPECT/CT and 99mTc-MDP SPECT/CT detected 20 and 18 bone metastases, with sensitivities of 80.0% (20/25) and 72.0% (18/25), specificities of 100.0% (49/49) and 81.3% (40/49), and AUCs of 88.0% and 84.9%, respectively. There was a significant difference in the AUC between the two imaging methods (P < 0.001). In an analysis of the number of bone metastasis lesions, the proportion of “typical metastasis” versus “equivocal metastasis” detected by the two imaging methods was 26.3:1 (PSMA) and 2.9:1 (MDP), and the difference was statistically significant (P = 0.005). There was a significant difference in the detection of bone metastatic lesions by 99mTc-PSMA and 99mTc-MDP when the maximum diameter of the lesions was ≤ 0.6 cm (P < 0.05). The optimal cut-off value for PSA was 2.635 ng/mL (PSMA) and 15.275 ng/mL (MDP). 99mTc-PSMA SPECT/CT led to a change in management to a more individualized therapy modality for 11 of 74 men (14.9%). 99mTc-PSMA SPECT/CT was superior to 99mTc-MDP SPECT/CT in the detection of bone metastases in PCa, especially for small lesions and in patients with low PSA levels, and demonstrated an additional benefit of providing information on extraskeletal metastases. With regard to therapy, 99mTc-PSMA scans might have utility in improving the subsequent therapy modality.https://doi.org/10.1038/s41598-022-20280-x |
| spellingShingle | Yu Zhang Zhiyi Lin Tao Li Yongbao Wei Mingdian Yu Liefu Ye Yuqing Cai Shengping Yang Yanmin Zhang Yuanying Shi Wenxin Chen Head-to-head comparison of 99mTc-PSMA and 99mTc-MDP SPECT/CT in diagnosing prostate cancer bone metastasis: a prospective, comparative imaging trial Scientific Reports |
| title | Head-to-head comparison of 99mTc-PSMA and 99mTc-MDP SPECT/CT in diagnosing prostate cancer bone metastasis: a prospective, comparative imaging trial |
| title_full | Head-to-head comparison of 99mTc-PSMA and 99mTc-MDP SPECT/CT in diagnosing prostate cancer bone metastasis: a prospective, comparative imaging trial |
| title_fullStr | Head-to-head comparison of 99mTc-PSMA and 99mTc-MDP SPECT/CT in diagnosing prostate cancer bone metastasis: a prospective, comparative imaging trial |
| title_full_unstemmed | Head-to-head comparison of 99mTc-PSMA and 99mTc-MDP SPECT/CT in diagnosing prostate cancer bone metastasis: a prospective, comparative imaging trial |
| title_short | Head-to-head comparison of 99mTc-PSMA and 99mTc-MDP SPECT/CT in diagnosing prostate cancer bone metastasis: a prospective, comparative imaging trial |
| title_sort | head to head comparison of 99mtc psma and 99mtc mdp spect ct in diagnosing prostate cancer bone metastasis a prospective comparative imaging trial |
| url | https://doi.org/10.1038/s41598-022-20280-x |
| work_keys_str_mv | AT yuzhang headtoheadcomparisonof99mtcpsmaand99mtcmdpspectctindiagnosingprostatecancerbonemetastasisaprospectivecomparativeimagingtrial AT zhiyilin headtoheadcomparisonof99mtcpsmaand99mtcmdpspectctindiagnosingprostatecancerbonemetastasisaprospectivecomparativeimagingtrial AT taoli headtoheadcomparisonof99mtcpsmaand99mtcmdpspectctindiagnosingprostatecancerbonemetastasisaprospectivecomparativeimagingtrial AT yongbaowei headtoheadcomparisonof99mtcpsmaand99mtcmdpspectctindiagnosingprostatecancerbonemetastasisaprospectivecomparativeimagingtrial AT mingdianyu headtoheadcomparisonof99mtcpsmaand99mtcmdpspectctindiagnosingprostatecancerbonemetastasisaprospectivecomparativeimagingtrial AT liefuye headtoheadcomparisonof99mtcpsmaand99mtcmdpspectctindiagnosingprostatecancerbonemetastasisaprospectivecomparativeimagingtrial AT yuqingcai headtoheadcomparisonof99mtcpsmaand99mtcmdpspectctindiagnosingprostatecancerbonemetastasisaprospectivecomparativeimagingtrial AT shengpingyang headtoheadcomparisonof99mtcpsmaand99mtcmdpspectctindiagnosingprostatecancerbonemetastasisaprospectivecomparativeimagingtrial AT yanminzhang headtoheadcomparisonof99mtcpsmaand99mtcmdpspectctindiagnosingprostatecancerbonemetastasisaprospectivecomparativeimagingtrial AT yuanyingshi headtoheadcomparisonof99mtcpsmaand99mtcmdpspectctindiagnosingprostatecancerbonemetastasisaprospectivecomparativeimagingtrial AT wenxinchen headtoheadcomparisonof99mtcpsmaand99mtcmdpspectctindiagnosingprostatecancerbonemetastasisaprospectivecomparativeimagingtrial |